Patents by Inventor John P. Koepke

John P. Koepke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension
    Publication number: 20040101523
    Abstract: Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as dopa-decarboxylase inhibitors, or as dopamine-&bgr;-hydroxylase inhibitors. These inhibitor compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kidney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension.
    Type: Application
    Filed: October 20, 2003
    Publication date: May 27, 2004
    Applicant: G.D. Searle & Co.
    Inventors: David B. Reitz, John P. Koepke, Edward H. Blaine, Joseph R. Schuh, Robert E. Manning, Glenn J. Smits
  • Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
    Publication number: 20030220521
    Abstract: Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as dopa-decarboxylase inhibitors, or as dopamine-&bgr;-hydroxylase inhibitors. These inhibitor compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kidney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension.
    Type: Application
    Filed: May 20, 2002
    Publication date: November 27, 2003
    Applicant: G.D. Searle & Co.
    Inventors: David B. Reitz, John P. Koepke, Edward H. Blaine, Joseph R. Schuh, Robert E. Manning, Glenn J. Smits